Concepedia
Statistics
Publications
8
Citations
921
H-Index
Active since
2005
Affiliations
Merck Serono S.p.A. (Italy)(Current)
Ono Pharmaceutical (United States)
Merck KGaA, Darmstadt (Germany)
Agenus (United States)
Nanfang Hospital
Bo Marelli is an author at Merck Serono S.p.A. (Italy) specializing in oncology, immunology, and cancer immunotherapy.
Publications per year
2005–2022
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan, Dong Zhang, Chunxiao Xu et al. · Science Translational Medicine · 2018 · 488 citations
Life Sciences, Immunology, Oncology +17
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
Yan Lan, Mahmoud Moustafa, Maximilian Knoll et al. · Cancer Cell · 2021 · 190 citations · Full text
Medicine, Immunology, Oncology +17
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Chunxiao Xu, Yanping Zhang, Alex Rolfe et al. · Clinical Cancer Research · 2017 · 79 citations
Cutting Edge: Epigenetic Regulation of <i>Foxp3</i> Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans
Jeremy D. Waight, Shinji Takai, Bo Marelli et al. · The Journal of Immunology · 2014 · 56 citations · Full text
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
Yan Lan, Tsz-Lun Yeung, Hui Huang et al. · Journal for ImmunoTherapy of Cancer · 2022 · 40 citations · Full text
1–5 of 8